---
title: Evaluating Alcohol Use in Alcoholic Liver Disease
nct_id: NCT03267069
overall_status: RECRUITING
sponsor: Nicole T Shen
study_type: OBSERVATIONAL
primary_condition: Alcoholic Liver Disease
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03267069.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03267069"
ct_last_update_post_date: 2019-03-13
last_seen_at: "2026-05-12T06:19:46.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Evaluating Alcohol Use in Alcoholic Liver Disease

**NCT ID:** [NCT03267069](https://clinicaltrials.gov/study/NCT03267069)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 160
- **Lead Sponsor:** Nicole T Shen
- **Conditions:** Alcoholic Liver Disease
- **Start Date:** 2016-11-27
- **Completion Date:** 2027-11-01
- **CT.gov Last Update:** 2019-03-13

## Brief Summary

This prospective, analytic observational study will investigate alcohol recidivism in patients with alcoholic liver disease. All adult subjects presenting with alcoholic liver disease are considered for inclusion. Subjects able to give consent are included.

## Detailed Description

This is a longitudinal observational study. Subjects with a diagnosis of alcoholic liver disease (acute alcoholic hepatitis or alcoholic cirrhosis) who present to Weill Cornell Medical Center or Columbia University Medical Center New York Presbyterian Hospital or the Gastroenterology and Hepatology Clinic will be invited to join this study, which entails a survey at baseline and follow-up at 3, 6, 9, 12, 15, and 18 months and then at 2, 5, and 10 years. Follow-up will consist of a chart review, a phone or in person interview, and most recent clinic visit interview for alcohol recidivism. The clinical providers will be blinded to the survey results.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* alcoholic liver disease able to consent

Exclusion Criteria:

* without alcoholic liver disease unable to consent
```

## Arms

- **alcohol liver disease** — Patients with alcohol liver disease consenting to participate in the study will be administered an initial survey at inclusion and then follow-up surveys at 3, 6, 9, 12, 15, and 18 month intervals and then 2, 5, and 10 years. There is no intervention cohort, all enrolled will complete the same surveys. Recidivism will be measured by responses to survey questions, clinical interviews documented in the chart, and urine ethnyl glucuronide or blood ethanol testing.

## Interventions

- **survey** (OTHER) — surveys will be administered at inclusion and follow-ups

## Primary Outcomes

- **alcohol recidivism assessed by questionnaire** _(time frame: 6 months)_ — Follow-up questionnaires will be administered at 6 months assessing for alcohol use
- **alcohol recidivism assessed by clinical interview** _(time frame: 6 months)_ — Follow-up interviews will be conducted at 6 months assessing for alcohol use
- **alcohol recidivism assessed by urine ethyl glucuronide** _(time frame: 6 months)_ — Follow-up urine testing may be conducted at 6 months assessing for alcohol use
- **alcohol recidivism assessed by blood** _(time frame: 6 months)_ — Follow-up blood testing may be conducted at 6 months assessing for alcohol use

## Secondary Outcomes

- **alcohol recidivism assessed by questionnaire** _(time frame: after 6 months)_
- **alcohol recidivism assessed by clinical interview** _(time frame: after 6 months)_
- **alcohol recidivism assessed by urine ethyl glucuronide** _(time frame: after 6 months)_
- **alcohol recidivism assessed by blood** _(time frame: after 6 months)_

## Locations (1)

- New York Presbyterian Hospital - Weill Cornell Medicine and Columbia University Medical Center, New York, New York, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.new york presbyterian hospital - weill cornell medicine and columbia university medical center|new york|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03267069.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03267069*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*